Use of disease modifying antirheumatic drugs (DMARDs) and/or oral corticosteroids, including start and stop date, were also collected at each follow-up visit.
Detailed data on fecal occult blood test (FOBT) restricted to the 5-year period before the reference date were also collected, including whether a test was positive or negative and the type of diagnostic test received following positive results.
In addition, other basic information including patients' age, sex, home address, visiting time and date is also collected.
Perinatal parameters such as neonates' sex, birth date, birth weight and length, gestational age, Apgar score, and ultrasonographic data were also collected after birth.
Other pathological characteristics of the tumor, such as differentiation, resection margin status, lymph node metastasis, TNM stage and information on tumor site, tumor size, serum level of CA19-9 at cancer diagnosis, major early symptoms, date of cancer diagnosis, date of tumor resection, date of recurrence, date of last follow-up, or date of death, were also collected.
Place of residence and date of birth were also collected.
